By Michelle A. Cissell, Ph.D. In 2007, JDRF took a calculated risk by creating the Network for Pancreatic Organ Donors with Diabetes (nPOD) to collect and distribute pancreatic and other tissues from deceased organ donors with type 1 diabetes (T1D), as well as from those without the disease but with multiple antibodies indicating high […]
JDRF-supported researchers have found that dysfunction of pancreatic beta cells precedes the onset of T1D in a mouse model of the disease. The study is the first direct demonstration that ER stress happens before the onset of T1D in an animal model. These findings help illuminate the earliest stages of T1D, and suggest that alleviating ER stress with drugs or other therapeutics might provide an avenue for slowing progression and onset of disease.
JDRF has partnered with San Diego–based medical company Dexcom, Inc. to support the manufacture of a so-called smart transmitter prototype, which will be available for research purposes before it will be commercially available. The technological advance not only would reduce the number of devices a person would have to wear with an artificial pancreas system, but would also enable wireless connectivity among these devices—an important feature that would give people with T1D the freedom of movement while participating in real-life outpatient studies.
JDRF and the Canadian government are expanding the Adolescent Type 1 Diabetes Cardio-Renal (heart and kidney) Intervention Trial (AdDIT) by adding one additional clinical site in southern Ontario, Canada. The expansion will serve to accelerate the recruitment of adolescents with type 1 diabetes (T1D) and microalbuminuria, a condition in which a protein called albumin leaks into the urine—a sign of early kidney disease and a risk factor for developing heart disease later in life.
In one of the largest studies of its kind, JDRF has partnered with iCo Therapeutics to investigate a potential new drug that could, if successful, broaden treatment options for people living with DME. The Phase II trial, led and coordinated by Johns Hopkins University investigators, is currently recruiting participants. To inquire about participation, please contact Dr. Quan Dong Nguyen or click here.
You could call them brothers-in-arms in the battle against type 1 diabetes (T1D): Maarten de Groot, founder and president of JDRF Netherlands, our organization’s newest international affiliate; and Bart Roep, M.D., Ph.D., a clinical immunologist who leads a T1D research team at Leiden University Medical Center, in the Netherlands. Dr. Roep is one of the […]
By Susan Learner Barr, M.S., R.D. There’s no end to what you can learn when visiting our nation’s capital. On February 18, more than 600 people, all sharing a connection to type 1 diabetes (T1D), attended the 2012 JDRF Type 1 Diabetes Research Summit hosted by the JDRF Capitol Chapter. A letter in the summit […]
By Michelle A. Cissell, Ph.D. Women know the importance of taking extra care of themselves before and during pregnancy—for the optimal health of their babies, as well as for their own well-being. For women with type 1 diabetes (T1D), diligent self-management both before and during pregnancy is especially crucial, as high blood glucose levels increase […]
By Jeffrey Brewer When JDRF was asked to submit an article to Diabetes, a medical journal of the American Diabetes Association (ADA), our organization’s leaders recognized the superb opportunity offered by this request. As a result, “Juvenile Diabetes Research Foundation: Mission, Strategy, and Priorities” was published in the January 2012 issue ofDiabetes in the journal’s “Perspectives in […]
Taking oral insulin in combination with low-dose anti-CD3 results in long-term reversal of type 1 diabetes in mice whose immune systems specifically attack insulin. The findings, if translated to humans, would help not only to identify people who are most likely to benefit from the therapy, but also to determine whether the therapy is working.